PSC
BBIO icon

Portman Square Capital’s BridgeBio Pharma BBIO Stock Holding History

Portman Square Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.95M Hold
133,600
– – 0.47% 52
2026
Q1 		$9.92M Buy
+133,600
New +$9.68M 0.38% 63
2025
Q1 		– Sell
-195,900
Closed -$5.38M – 229
2024
Q4 		$5.38M Sell
195,900
-40,300
-17% -$1.04M 0.19% 117
2024
Q3 		$6.01M Hold
236,200
– – 0.22% 133
2024
Q2 		$5.98M Buy
+236,200
New +$6.46M 0.21% 137

Other funds holding BBIO

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
MMA
Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Portman Square Capital's BBIO Position: Q4 2025 in Review

Portman Square Capital sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 117,826 shares — an estimated $7.73M sold.

Portman Square Capital first reported a position in BBIO in Q3 2023 and held it in 9 quarters. The position peaked at $6.29M in Q2 2025. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Portman Square Capital reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Portman Square Capital sold 117,826 BridgeBio Pharma shares in Q4 2025, an estimated $7.73M.
  • Portman Square Capital first reported a position in BridgeBio Pharma in Q3 2023 and held it in 9 quarters.
  • Portman Square Capital's BridgeBio Pharma position peaked at $6.29M in Q2 2025.
  • 432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Portman Square Capital's 13F filing for Q4 2025, filed 23 Jan 2026.